Abstract Details

Title Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Baseline Demographic and Clinical Characteristics

Topic Movement Disorders

Presentation(s) P07 - (-)

Poster/Presentation
Number 190

Objective

Background BACKGROUND: CD PROBE is the largest longitudinal registry evaluating the treatment of CD with onabotulinumtoxinA (BOTOX®) (NCT00836017).

Design/Methods DESIGN/METHODS: Prospective, open-label, multi-center, observational registry of CD in subjects new to the physician's practice, ?16 weeks since any treatment with botulinum toxin, or toxin naive (Jankovic J, et al. BMC Neurology. 2011;11:140). Baseline variables and physician clinical assessment of disease severity were analyzed.

Results RESULTS: As of 10/4/2012, 1046 subjects, mean age 58.0 ± 14.7 years, 74.3% female, were enrolled in CD PROBE. The mean age at symptom onset was 49.0 ± 16.7 years, time from CD onset to diagnosis was 5.0 ± 8.1 years, and time from CD diagnosis to first treatment was 1.1 ± 4.2 years. The majority (63.5%) were toxin naive at baseline. At enrollment, 11.7% considered themselves "disabled." Torticollis was the most common CD subtype (47.5%), followed by laterocollis (39.0%), anterocollis (5.7%), retrocollis (5.3%), and other abnormal postures (2.5%). The mean Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score was 38.8 ± 13.1 (Severity subscale: 17.3 ± 5.3, Disability subscale: 11.1 ± 6.4, Pain subscale: 10.5 ± 5.1). Mean Cervical Dystonia Impact Profile (CDIP-58) subscale scores at baseline ranged between 44.7 ± 24.6 (walking) to 70.7 ± 22.8 (pain and discomfort). The various pain measures, including TWSTRS pain subscale, CDIP-58 pain subscale, and Pain Numeric Rating Scale, were all significantly inter-correlated (p?0.0001).

Conclusions CONCLUSIONS: CD PROBE will continue to provide important clinical information from the largest CD cohort followed prospectively after treatment with onabotulinumtoxinA. The baseline data provide evidence for 3:1 female preponderance, 50 years mean age at onset, high frequency of pain and disability, and >6 years latency from onset of symptoms to treatment.

Authors/Disclosures
Joseph Jankovic, MD, FAAN (Baylor College of Medicine) PRESENTER	Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance. Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance, Allergan. The institution of Dr. Jankovic has received research support from Baylor College of Medicine. Dr. Jankovic has received research support from Abbvie. The institution of Dr. Jankovic has received research support from Abbvie.
P. D. Charles, MD, FAAN (Vanderbilt University Medical Center)	Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iota. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceraxis. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspen Neuroscience. Dr. Charles has stock in Arena Therapeutics. The institution of Dr. Charles has received research support from Pharma 2 B. The institution of Dr. Charles has received research support from Intec. The institution of Dr. Charles has received research support from Merz. The institution of Dr. Charles has received research support from Novartis. The institution of Dr. Charles has received research support from Aeon. The institution of Dr. Charles has received research support from Impax. The institution of Dr. Charles has received research support from AskBio. The institution of Dr. Charles has received research support from BlueRock. The institution of Dr. Charles has received research support from AbbVie. The institution of Dr. Charles has received research support from Ipsen.
Charles H. Adler, MD, PhD, FAAN (Mayo Clinic Arizona)	Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Adler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CND Life Sci. Dr. Adler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precon. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Dr. Adler has received research support from NIH. The institution of Dr. Adler has received research support from Michael J. Fox Foundation. The institution of Dr. Adler has received research support from Arizona Biomedical Research Commission. Dr. Adler has received publishing royalties from a publication relating to health care.
Cynthia L. Comella, MD, FAAN (Rush University Medical Center)	Dr. Comella has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Comella has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vima. Dr. Comella has received publishing royalties from a publication relating to health care. Dr. Comella has received publishing royalties from a publication relating to health care.
Mark Stacy, MD (MUSC Department of Neurology)	Dr. Stacy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biovie. Dr. Stacy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for National Institute of Aging. Dr. Stacy has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Dartmouth. Dr. Stacy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorders Journal.
	No disclosure on file
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.
Mitchell F. Brin, MD, FAAN (Abbvie / UC Irvine)	Dr. Brin has received personal compensation for serving as an employee of Allergan. Dr. Brin has stock in Allergan.

��ɫ��

��ɫ��